Pharmacokinetics and Safety of Levetiracetam Extended-Release Tablets and Relative Bioavailability Compared with Immediate-Release Tablets in Healthy Chinese Subjects

2018 ◽  
Vol 43 (4) ◽  
pp. 405-413
Author(s):  
Meng Wang ◽  
Mengmeng Wang ◽  
Quanying Zhang ◽  
Shunlin Zong ◽  
Chengzhe Lv
Keyword(s):  
Extended Release ◽  
Immediate Release ◽  
Relative Bioavailability ◽  
Healthy Chinese ◽  
Chinese Subjects

scholarly journals Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study

2016 ◽  
Vol 60 (4) ◽  
pp. 2492-2498 ◽  
Author(s):  
Marcelo Gomes Davanço ◽  
Michel Leandro Campos ◽  
Talita Atanazio Rosa ◽  
Elias Carvalho Padilha ◽  
Alejandro Henao Alzate ◽  
...  
Keyword(s):  
Chagas Disease ◽  
Extended Release ◽  
Hydroxypropyl Methylcellulose ◽  
Immediate Release ◽  
Relative Bioavailability ◽  
Pharmacokinetic Parameters ◽  
Therapeutic Success ◽  
Preclinical Pharmacokinetics ◽  
Bioavailability Study

ABSTRACTBenznidazole (BNZ) is the first-line drug for the treatment of Chagas disease. The drug is available in the form of immediate-release tablets for 100-mg (adult) and 12.5-mg (pediatric) doses. The drug is administered two or three times daily for 60 days. The high frequency of daily administrations and the long period of treatment are factors that significantly contribute to the abandonment of therapy, affecting therapeutic success. Accordingly, this study aimed to evaluate the preclinical pharmacokinetics of BNZ administered as extended-release tablets (200-mg dose) formulated with different types of polymers (hydroxypropyl methylcellulose K4M and K100M), compared to the tablets currently available. The studies were conducted with rabbits, and BNZ quantification was performed in plasma and urine by ultraperformance liquid chromatography methods previously validated. The bioavailability of BNZ was adequate in the administration of extended-release tablets; however, with the administration of the pediatric tablet, the bioavailability was lower than with other tablets, which showed that the clinical use of this formulation should be monitored. The pharmacokinetic parameters demonstrated that the extended-release tablets prolonged drug release from the pharmaceutical matrix and provided an increase in the maintenance of the drug concentrationin vivo, which would allow the frequency of administration to be reduced. Thus, a relative bioavailability study in humans will be planned for implementation of a new product for the treatment of Chagas disease.

Relative bioavailability study of linagliptin/ metformin tablets in healthy Chinese subjects

2015 ◽  
Vol 53 (07) ◽  
pp. 582-593 ◽  
Author(s):  
Solen Pichereau ◽  
Xia Zhao ◽  
Yimin Cui ◽  
Shuai Zhao ◽  
Kathrin Hohl ◽  
...  
Keyword(s):  
Relative Bioavailability ◽  
Bioavailability Study ◽  
Healthy Chinese ◽  
Chinese Subjects

Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects

2010 ◽  
Vol 25 (5) ◽  
pp. 404-409 ◽  
Author(s):  
Si Tianmei ◽  
Shu Liang ◽  
Liu Yi ◽  
Su Yun'Ai ◽  
Guo Chunmei ◽  
...  
Keyword(s):  
Single Dose ◽  
Extended Release ◽  
Healthy Chinese ◽  
Chinese Subjects ◽  
Paliperidone Extended Release
Sign in / Sign up

Export Citation Format

Share Document